Decreased occludin staining in PC-3 HAVcR-1EXP and increased staining in PC-3 HAVcR-1KD suggests that the overexpression of HAVcR-1 would decrease TJ integrity and that targeting HAVcR-1 could, therefore, be a potential therapeutic target for prostate cancer. This evidence concerns the gene OCLN and prostate cancer.